ABBV News & Events

Stock indexes retreated amid losses for the heavyweight chip sector, making the Nasdaq the laggard, while the Dow pulled back from a record high reached in morning trading. Memory producers sank even though Samsung posted a 19-fold surge in profit last quarter. The surge was in line with the sector's rally this year, but markets appear to be growing increasingly skeptical on whether AI hyperscalers can justify elevated levels of capital expenditure on infrastructure. Yields edged higher after attacks on an LNG tanker in the Middle East tempered hopes of lower energy inflation.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. v1. STOCK NEWS:Walmartsaid it would cut prices on many summer staplesfrom President Trump saying the retail giant was doing so at his requestChina's DeepSeek is developing its own AI chip in a push to reduce reliance on Nvidiaand Huawei chips,Vertex Pharmaceuticalsto acquire Crinetics Pharmaceuticalsfor $85 per share in cash, for a total equity value of approximately $10BSamsung Electronicsreported, but the AI-fueled earnings still failed to meet high investor expectationsMetadebuted its, saying it will help power image generation in Meta Advantage+ creative "in the coming weeks"2. WALL STREET CALLS:Wall Streetof SpaceX, including Raymond James starting the stock with a Strong Buy rating and $800 price targetScotiabankCloudflareto OutperformBofAAdobeat Underperform with a $190 price target, down from the Buy rating the firm previously heldDeutsche BankFirst Solarto BuyMelius ResearchAmerican Airlinesto Hold3. AROUND THE WEB:Big banks have held talks in recent months to buy a card network owned by Fiserv, Reuters and WSJ reportMicrosoftwill replace OpenAI and Anthropic with its own AI in some apps, Bloomberg saysMetasaid four states are seeking $1.4T in penalties over accusations it designed its social media platforms to addict young users and misled the public on their safety, Reuters reportsAmazonis seeking to raise at least $25B through a U.S. dollar bond sale to fund investments in artificial intelligence infrastructure, Bloomberg reportsPresident Trump is expected to support a potential sale of Lockheed Martin'sF-35 Lightning II jets to Turkey during a visit to Ankara, Reuters says4. MOVERS:Digital Oceangained afterit expects Q2 RPO to exceed $800MRedwood Trustwas higher after highlightingFigmaincreased after BofAcoverage with a Buy ratingRivianwas lower after75M shares of stockUnited States Antimonyfell after announcing the5. EARNINGS/GUIDANCE:Interactive Strengthraised itsCosmos HealthreportedShellissued anAbbVieprovided itsand cut its guidance for FY26Sealsqreportedand backed its guidance for FY26INDEXES:The Dow fell 130.76, or 0.25%, to 52,925.15, the Nasdaq lost 302.47, or 1.16%, to 25,818.69, and the S&P 500 declined 33.58, or 0.45%, to 7,503.85.

Risk-on sentiment resurfaced following the long holiday weekend as large-cap growth areas of the market handily outperformed SMIDs and value.  Comms Services, Tech, and Financials were the best performing sectors on the S&P 500, while the defensively oriented  Healthcare, Staples, and Utilities lagged.  Computer Hardware had an especially strong day - Arista Networkswas up 8.3%, Western Digitalgained 7.1% and Seagaterallied 5.9%.   A softer than expected non-farm payrolls dented expectations of tightening, but that narrative was also defied by the price action in the Treasury market as yields on the short-end of the curve remained elevated while longer-dated maturities remain elevated.   Service ISM data also came in softer somewhat, though the indicator remained in expansion - as it has for the past two years.In the evening hours, equity index futures are mixed - S&P e-minis are flat while Nasdaq 100 is off by 0.2%.  In commodities, WTI Crude Oil is marginally higher but still below $70 per barrel while precious and base metals are up by about 0.2%.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER -Crinetics Pharmaceuticalsup 100% after being acquired by Vertex Pharmaceuticals, which is down 2.3%Aligos Therapeuticsup 14.9% after receiving a $25M upfront payment for pevifoscorvir sodium license dealFirst Solarup 2.1% after being upgraded to buy at Deutsche BankRentokil Initial plcup 1.9% after being upgraded to Buy at Goldman SachsAbbVieup 0.3% after Q2 pre-announcementLOWER -Riviandown 8.8% after 75M share equity offering.

AbbVie sees Q2 adjusted EPS ex-items $3.57-$3.61, consensus $3.77

In a regulatory filing, AbbVie said that reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2026 are expected to include acquired IPR&D and milestones expense of $291 million on a pre-tax basis, representing an unfavorable impact of $0.17 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended June 30, 2026 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates. While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions.